Human noroviruses (HuNoVs) are the most common cause of viral gastroenteritis resulting in ~219,000 deaths annually and a societal cost of ~USD60 billion. There are no antivirals or vaccines available to treat and/or prevent HuNoV. In this study, we performed a large-scale phe-notypical antiviral screening using the mouse norovirus (MNV), which included ~1000 drug-like small molecules from the Drug Design and Synthesis Centre (Sapienza University, Rome). Compound 3-((3,5-dimethylphenyl)sulfonyl)-5-chloroindole-N-(phenylmethanol-4-yl)-2.carboxamide (compound 1) was identified as an inhibitor of MNV replication with an EC50 of 0.5 ± 0.1 µM. A series of 10 analogs were synthesized of which compound 6 showed an improved potency/selectiv-ity (EC50 0.2 ± 0.1 µM) against MNV; good activity was also observed against the HuNoV GI replicon (EC50 1.2 ± 0.6 µM). Time-of-drug-addition studies revealed that analog 6 acts at a time point that coincides with the onset of viral RNA replication. After six months of selective pressure, two compound 6res variants were independently selected, both harboring one mutation in VPg and three mutations in the RdRp. After reverse engineering S131T and Y154F as single mutations into the MNV backbone, we did not find a markedly compound 6res phenotype. In this study, we present a class of novel norovirus inhibitors with a high barrier to resistance and in vitro antiviral activity.

Discovery of a novel class of norovirus inhibitors with high barrier of resistance / Van Dycke, J.; Puxeddu, M.; La Regina, G.; Mastrangelo, E.; Tarantino, D.; Rymenants, J.; Sebastiani, J.; Nalli, M.; Matthijnssens, J.; Neyts, J.; Silvestri, R.; Rocha-Pereira, J.. - In: PHARMACEUTICALS. - ISSN 1424-8247. - 14:10(2021). [10.3390/ph14101006]

Discovery of a novel class of norovirus inhibitors with high barrier of resistance

Puxeddu M.;La Regina G.;Sebastiani J.;Nalli M.;Silvestri R.;
2021

Abstract

Human noroviruses (HuNoVs) are the most common cause of viral gastroenteritis resulting in ~219,000 deaths annually and a societal cost of ~USD60 billion. There are no antivirals or vaccines available to treat and/or prevent HuNoV. In this study, we performed a large-scale phe-notypical antiviral screening using the mouse norovirus (MNV), which included ~1000 drug-like small molecules from the Drug Design and Synthesis Centre (Sapienza University, Rome). Compound 3-((3,5-dimethylphenyl)sulfonyl)-5-chloroindole-N-(phenylmethanol-4-yl)-2.carboxamide (compound 1) was identified as an inhibitor of MNV replication with an EC50 of 0.5 ± 0.1 µM. A series of 10 analogs were synthesized of which compound 6 showed an improved potency/selectiv-ity (EC50 0.2 ± 0.1 µM) against MNV; good activity was also observed against the HuNoV GI replicon (EC50 1.2 ± 0.6 µM). Time-of-drug-addition studies revealed that analog 6 acts at a time point that coincides with the onset of viral RNA replication. After six months of selective pressure, two compound 6res variants were independently selected, both harboring one mutation in VPg and three mutations in the RdRp. After reverse engineering S131T and Y154F as single mutations into the MNV backbone, we did not find a markedly compound 6res phenotype. In this study, we present a class of novel norovirus inhibitors with a high barrier to resistance and in vitro antiviral activity.
2021
Caliciviridae; in vitro; Norovirus; small molecule
01 Pubblicazione su rivista::01a Articolo in rivista
Discovery of a novel class of norovirus inhibitors with high barrier of resistance / Van Dycke, J.; Puxeddu, M.; La Regina, G.; Mastrangelo, E.; Tarantino, D.; Rymenants, J.; Sebastiani, J.; Nalli, M.; Matthijnssens, J.; Neyts, J.; Silvestri, R.; Rocha-Pereira, J.. - In: PHARMACEUTICALS. - ISSN 1424-8247. - 14:10(2021). [10.3390/ph14101006]
File allegati a questo prodotto
File Dimensione Formato  
Van-Dicke_Discovery_2021.pdf

accesso aperto

Tipologia: Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza: Creative commons
Dimensione 738.96 kB
Formato Adobe PDF
738.96 kB Adobe PDF

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/1604507
Citazioni
  • ???jsp.display-item.citation.pmc??? 0
  • Scopus 1
  • ???jsp.display-item.citation.isi??? 0
social impact